What's New in the ATA Guidelines for Thyroid Nodules and Differentiated Cancer?

Saturday, October 11, 2025

11:30 AM - 12:20 PM EDT

Location: Wabash Ballroom 3

Disclosure(s):

David L. Steward, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Alice L. Tang, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Marika D. Russell, MD, FACS:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Matthew D. RIngel, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

PROGRAM DESCRIPTION: The American Thyroid Association (ATA) is set to release its updated guidelines for the management of differentiated thyroid cancer. These guidelines reflect the latest advancements in evidence-based best practices, addressing critical updates in diagnosis, treatment, and long-term care strategies.

In this session, expert panelists, including an endocrinologist, who served as coauthors of the new ATA guidelines will provide an exclusive preview of key changes and innovations incorporated into this much-anticipated update. Attendees will gain early insights into evolving recommendations on risk stratification, surgical approaches, radioactive iodine use, and novel therapies for advanced disease. The discussion will also address how these updates aim to enhance patient outcomes and optimize personalized care in a rapidly changing clinical landscape.

This presentation is essential for comprehensive otolaryngologists managing thyroid cancer patients. It will offer a unique opportunity to hear directly from thought leaders actively shaping the future of thyroid cancer care, providing practical guidance for implementing these updates into clinical practice.

OUTCOME OBJECTIVE 1: Highlight important changes in the new ATA guidelines for the treatment of thyroid cancer

OUTCOME OBJECTIVE 2: Application of these changes in the guidelines highlighted in case-based scenarios

OUTCOME OBJECTIVE 3: Provide and describe the evidence and rationale behind the new changes in the updated guidelines

BACKGROUND STATEMENT: This topic is highly relevant for the 2025 Meeting as it provides otolaryngologists with the latest, evidence-driven recommendations to enhance patient outcomes, optimize treatment approaches, and navigate emerging therapies for thyroid cancer.

Comprehensive Otolaryngology Track Statement :

Panelist(s)

DS

David L. Steward, MD

H.B. Broidy Professor and Chair
University of Cincinnati
Cincinnati, OH, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Moderator(s)

Alice L. Tang, MD

Associate Professor
University of Cincinnati
Cincinnati, OH, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Panelist(s)

MR

Marika D. Russell, MD, FACS

Assistant Professor, Otolaryngology - Head and Neck Surgery
Massachusetts Eye and Ear Infirmary/Harvard Medical School
Boston, MA, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.
Matthew D. RIngel, MD

Chair , Department of Molecular Medicine and Therapeutics; Deputy Director for Basic Research
The Ohio State University College of Medicine and Comprehensive Cancer Center
Columbus, OH, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.